(NASDAQ: CNSY) Cerenome's forecast annual revenue growth rate of 119.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.3%.
Cerenome's revenue in 2026 is $4,203,000.On average, 5 Wall Street analysts forecast CNSY's revenue for 2026 to be $32,589,850, with the lowest CNSY revenue forecast at $22,313,498, and the highest CNSY revenue forecast at $41,682,221. On average, 5 Wall Street analysts forecast CNSY's revenue for 2027 to be $156,126,176, with the lowest CNSY revenue forecast at $74,378,325, and the highest CNSY revenue forecast at $223,134,975.
In 2028, CNSY is forecast to generate $352,887,204 in revenue, with the lowest revenue forecast at $298,773,178 and the highest revenue forecast at $406,424,419.